Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
53.38
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
38
39
Next >
3 Stocks That Are Reshaping the Future
↗
May 16, 2023
As the population ages and AI develops, these three companies stand out among stocks reshaping the future.
Via
InvestorPlace
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
May 16, 2023
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
Via
MarketBeat
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
↗
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
May 09, 2023
From
Genentech
Via
Business Wire
Is Roche a Buy Now?
↗
March 20, 2023
Roche focuses on the long-term.
Via
The Motley Fool
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
May 05, 2023
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.
Via
MarketBeat
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
↗
May 04, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.
Via
Benzinga
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish
↗
April 28, 2023
Tempest Therapeutics Inc (NASDAQ: TPST) announced
Via
Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
↗
April 27, 2023
The company reported lighter-than-expected declines due to Keytruda and Gardasil.
Via
Investor's Business Daily
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline
↗
April 26, 2023
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)
Via
Benzinga
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
↗
April 26, 2023
Both GSK and Roche experienced declining Covid-related sales in the first quarter.
Via
Investor's Business Daily
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
↗
April 26, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at...
Via
Benzinga
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
April 25, 2023
From
Genentech
Via
Business Wire
3 Top Biotech Stocks Defying the Bear Market
↗
April 25, 2023
All three companies have therapies with strong sales potential.
Via
The Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
↗
April 25, 2023
The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.
Via
Benzinga
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
April 24, 2023
From
Genentech
Via
Business Wire
Biogen To Report Q1 Earnings: Here's What To Expect
↗
April 21, 2023
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%.
Via
Talk Markets
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma
↗
April 20, 2023
Via
Benzinga
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
April 19, 2023
From
Genentech
Via
Business Wire
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
April 16, 2023
From
Genentech
Via
Business Wire
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
↗
April 13, 2023
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...
Via
Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
↗
April 13, 2023
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.
Via
Investor's Business Daily
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
April 13, 2023
From
Genentech
Via
Business Wire
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
↗
April 11, 2023
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Via
The Motley Fool
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
↗
April 10, 2023
Shares are closing in on a buy point out of a consolidation.
Via
Investor's Business Daily
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
↗
March 30, 2023
Via
Benzinga
Roche's Slow Growth Shouldn't Drive Investors Away
↗
March 28, 2023
New treatments for various cancers, eye diseases, and more may bring in future revenues.
Via
The Motley Fool
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
↗
March 22, 2023
Via
Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
↗
March 20, 2023
Via
Benzinga
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
March 20, 2023
From
Genentech
Via
Business Wire
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
38
39
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
